Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea

Botulinum therapy for cerebral palsy (CP) is considered not only as one of the effective approaches for the treatment of increased muscle tone and spasticity, but also as a method of excessive salivation correction. The article presents an overview of the results of Russian and foreign studies on the efficacy and safety of incobotulinumtoxinA for the treatment of spasticity of the lower and upper limbs, as well as sialorrhea in patients with CP. The article also provides a consensus opinion of Russian specialists working with patients with CP and using Xeomin (incobotulinumtoxinA) in their practice for the treatment of spasticity and sialorrhea. This consensus was based on the results of a Russian retrospective multicenter study on the use of incobotulinumtoxinA for the treatment of spasticity and sialorrhea in CP, data from recently published international clinical trials, and our own clinical experience. We present detailed practical recommendations on the calculation of the total dose of incobotulinumtoxinA per procedure for the treatment of spasticity in CP, on the calculation of incobotulinumtoxinA dose for the most common target muscles (lower and upper limbs) for spasticity treatment in CP, on incobotulinumtoxinA dilution and dose calculation for sialorrhea treatment in children, on incobotulinumtoxinA dilution and dose calculation for simultaneous treatment of spasticity and sialorrhea in CP. We justify incobotulinumtoxinA use, when simultaneous treatment of spasticity and sialorrhea is necessary, which allows reducing the intervals between repeated injection cycles. IncobotulinumtoxinA use in children with CP demonstrates a favorable safety profile, including long-term use.

1. Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral palsy: current opinions on definition, epidemiology, risk factors, classification and treatment options. Neuropsychiatr Dis Treat. 2020 Jun 12;16:1505-1518. doi: 10.2147/NDT.S235165

2. Graham HK, Rosenbaum P, Paneth N, et al. Cerebralpalsy. Nat Rev Dis Primers. 2016 Jan 7;2:15082. doi: 10.1038/nrdp.2015.82

3. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010 Jan;14(1):45-66. doi: 10.1016/j.ejpn.2009.09.005. Epub 2009 Nov 14.

4. Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi: 10.1007/s11910-020-1022-z

5. Delgado MR, Bonikowski M, Carranza J, et al. Safety and efficacy of repeat open-label abobotulinumtoxinA treatment in pediatric cerebral palsy. J Child Neurol. 2017 Nov;32(13):1058-64. doi: 10.1177/0883073817729918. Epub 2017 Sep 15.

6. Heinen F, Kanovsky P, Schroeder AS, et al. IncobotulinumtoxinA for the treatment of lowerlimb spasticity in children and adolescents with cerebral palsy: A phase 3 study. J Pediatr Rehabil Med. 2021;14(2):183-97. doi: 10.3233/PRM-210040

7. Kanovsky P, Heinen F, Schroeder AS, et al. Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebralpalsy. J Pediatr Rehabil Med. 2021 Dec

8. doi: 10.3233/PRM-210041. Epub ahead of print. 8. Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015 May 11;7(5):1629-48. doi: 10.3390/toxins7051629

9. Kurenkov AL, Klochkova OA, Kuzenkova LM, et al. Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV–V). Zhurnal nevrologi i ipsihiatrii imeni S.S. Korsakova. 2020;120(12):57-66. doi: 10.17116/jnevro202012012157 (In Russ.).

10. Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am. 2006 Jan;88(1):161-70. doi: 10.2106/JBJS.C.01497

11. Orthopedic treatment of foot deformities in children with cerebral palsy: Abstract of the thesis. diss. … doc. med. sci]. St. Petersburg; 2014. 45 p. (In Russ.).

12. Zmanovskaya VA, Levitina EV, Popkov DA, et al. Botulinumtoxin type A (dysport) in the complex rehabilitation of children with spastic forms of cerebralpalsy. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2014;114(7):33-6 (In Russ.).

13. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 2017 Mar 2;3(3):CD006499. doi: 10.1002/14651858.CD006499.pub4

14. Berweck S, Bonikowski M, Kim H, et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021 Aug 2;97(14):e1425-e1436. doi: 10.1212/WNL.0000000000012573. Online ahead of print.

15. Jost WH, Steffen A, Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert Rev Neurother. 2021 Oct;21(10):1059-68. doi: 10.1080/14737175.2021.1979959. Epub 2021 Oct 4.

16. Love SC, Novak I, Kentish M, et al.; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010 Aug;17 Suppl 2:9-37. doi: 10.1111/j.1468-1331.2010.03126.x

17. Spasticity in children and young people with non-progressive brain disorders. London: Published by the RCOG Press at the Royal College of Obstetricians and Gynaecologists; 2012. 298 p.

18. Kurenkov AL, Klochkova OA, Kuzenkova LM, et al. Efficacy and safety of botulinumtoxintype А (IncobotulinumtoxinA) in treatment of cerebralpal sypatients. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2017;117(11):33-6 (In Russ.).

19. Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol. 2016;20(4):532-7.

20. Leon-Valenzuela A, Palacios JS, Del Pino Algarrada R. IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability. BMC Neurol. 2020 Apr 8;20(1):126. doi: 10.1186/s12883-020-01702-7

21. Dabrowski E, Chambers HG, Gaebler-Spira D, et al. IncobotulinumtoxinA efficacy/safety in upper-limb spasticity in pediatric cerebral palsy: randomized controlled trial. Pediatr Neurol. 2021 Oct;123:10-20. doi: 10.1016/j.pediatrneurol. 2021.05.014. Epub 2021 May 21.

22. Kurenkov AL, Kuzenkova LM, Chernikov VV, et al. The use of IncobotulinumtoxinA for the treatment of sialorrhea in patients with cerebralpalsy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):52-9. doi: 10.14412/2074- 2711-2021-4-52-59 (In Russ.).

23. Kurenkov AL, Agranovich OV, Kuzenkova LM, et al. Doses election of IncobotulinumtoxinA for the treatment of spasticity and sialorrhea in cerebralpalsy: results of a retrospective multicenter study. Nevrologicheskiy zhurnal im. L.O. Badalyana. 2021;2(4):189-202. doi: 10.46563/2686-8997-2021-2-4-189-202 (In Russ.).

24. Almina S, Karile Y, Audrone P, Indre B. Analgesic effect of botulinum toxin in children with cerebral palsy: A systematic review. Toxicon. 2021 Aug;199:60-67. doi: 10.1016/j.toxicon.2021.05.012. Epub 2021 Jun 1.

25. Khachatryan LG, Lyalina AA, Zotova NS, et al. Efficacy botulinum toxin type A in children with muscular dystonia. Voprosy prakticheskoy pediatrii. 2019;14(3):58-67. doi: 10.20953/1817-7646-2019-3-58-67 (In Russ.).